The evolving landscape of antibody–drug conjugates: In depth analysis of recent research progress
Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …
The role of innate immune genes in Alzheimer's disease
Targeting neuroinflammation via CD33 inhibition and/or TREM2 activation may have
important implications for neurodegeneration in Alzheimer's disease and may be an addition …
important implications for neurodegeneration in Alzheimer's disease and may be an addition …
Symptomatic and disease-modifying therapy pipeline for Alzheimer's disease: Towards a personalized polypharmacology patient-centered approach
Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …
Evaluation of CD33 as a genetic risk factor for Alzheimer's disease
In 2011, genome-wide association studies implicated a polymorphism near CD33 as a
genetic risk factor for Alzheimer's disease. This finding sparked interest in this member of the …
genetic risk factor for Alzheimer's disease. This finding sparked interest in this member of the …
Human sialoglycan ligands for immune inhibitory Siglecs
A Gonzalez-Gil, TA Li, J Kim, RL Schnaar - Molecular Aspects of Medicine, 2023 - Elsevier
Most human Siglecs (sialic acid binding immunoglobulin-like lectins) are expressed on the
surfaces of overlapping subsets of immune cells, and most carry immunoreceptor tyrosine …
surfaces of overlapping subsets of immune cells, and most carry immunoreceptor tyrosine …
Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery
Cancer patients with malignant involvement of tumor-draining lymph nodes (TDLNs) and
distant metastases have the poorest prognosis. A drug delivery platform that targets the …
distant metastases have the poorest prognosis. A drug delivery platform that targets the …
Sialic acid—modified nanoparticles—new approaches in the glioma management—perspective review
P Wielgat, K Niemirowicz-Laskowska… - International Journal of …, 2021 - mdpi.com
The cell surface is covered by a dense and complex network of glycans attached to the
membrane proteins and lipids. In gliomas, the aberrant sialylation, as the final stage of …
membrane proteins and lipids. In gliomas, the aberrant sialylation, as the final stage of …
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on …
Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody linked to
calicheamicin, a DNA damaging agent, and is a well-established therapeutic for treating …
calicheamicin, a DNA damaging agent, and is a well-established therapeutic for treating …
Acute Promyelocytic Leukemia (APL): A Review of the Classic and Emerging Target Therapies towards Molecular Heterogeneity
TD de Almeida, FCG Evangelista, AP Sabino - Future Pharmacology, 2023 - mdpi.com
The occurrence of severe bleeding syndrome because of the PML-RARα fusion protein is a
life-threatening event in APL. This protein destabilizes homeostasis, maturation, remodeling …
life-threatening event in APL. This protein destabilizes homeostasis, maturation, remodeling …